Table 3.
Gene | Cosinor parameters | Tissue
|
P-value | ||
---|---|---|---|---|---|
N | P | C | |||
PER1 | Mesor | 1.60±0.11 | 1.20±0.06 | 0.88±0.04 | 0.000a (F=48.137) |
Amplitude | 0.81±0.01 | 0.71±0.01 | 0.54±0.04 | 0.000a (F=92.659) | |
Acrophase (HALO) | 16.93±0.04 | 7.27±0.06 | 16.73±0.18 | 0.000c (F=7,294.436) | |
VEGF | Mesor | 2.26±0.21 | 3.51±0.33 | 6.86±0.59 | 0.000a (F=71.351) |
Amplitude | 0.82±0.01 | 2.06±0.23 | 1.91±0.06 | 0.000b (F=71.938) | |
Acrophase (HALO) | 9.93±0.91 | 6.21±0.24 | 1.04±0.95 | 0.000a (F=100.324) | |
KI67 | Mesor | 0.85±0.42 | 1.34±0.76 | – | 0.000a (F=12.387) |
Amplitude | 0.39±0.07 | 0.66±0.03 | – | 0.013a (F=17.970) | |
Acrophase (HALO) | 1.65±0.71 | 19.93±0.74 | – | 0.003a (F=42.501) | |
C-MYC | Mesor | 1.71±0.10 | 3.39±0.03 | 4.22±0.11 | 0.000a (F=543.026) |
Amplitude | 0.83±0.06 | 1.74±0.01 | 1.87±0.04 | 0.000b (F=574.424) | |
Acrophase (HALO) | 7.78±0.57 | 3.92±0.55 | 23.93±0.06 | 0.000a (F=1,607.264) | |
P53 | Mesor | 3.34±0.19 | 2.33±0.26 | 1.27±0.21 | 0.000a (F=82.040) |
Amplitude | 1.92±0.13 | 0.86±0.08 | 0.45±0.07 | 0.000a (F=109.770) | |
Acrophase (HALO) | 20.47±0.81 | 23.87±0.89 | 21.06±0.73 | 0.005c (F=14.995) |
Notes: The daily rhythm is described as mesor, amplitude, and acrophase. P<0.05 represents that there is a significant difference. P-value represents the results of differences in each cosinor parameter of each gene in three groups analyzed by one-way ANOVA. Superscripts “a”, “b”, and “c” represent the results of the intergroup differences analyzed by Student–Newman–Keuls test after the one-way ANOVA, as follows:
There are mutual significant differences in three groups.
There are significant differences between P or C group and N group, but there is no significant difference between P and C groups.
There are significant differences between P group and C or N group, but there is no significant difference between C and N groups.
Abbreviations: N, normal buccal mucosa; P, precancerous lesion; C, cancer; HALO, hours after light onset; ANOVA, analysis of variance.